Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology

[at noodls] – Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of SEAMLESS … more

View todays social media effects on CYCCP

View the latest stocks trending across Twitter. Click to view dashboard